Drug Profile
3DP 4815
Latest Information Update: 03 Mar 2008
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arterial thrombosis; Venous thrombosis
Most Recent Events
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
- 24 Jan 2001 Centocor has licensed 3DP 4815 from 3-Dimensional Pharmaceuticals for the world
- 17 Feb 2000 Phase-I clinical trials for Arterial thrombosis in USA (PO)